Roquefort Therapeutics (LON:ROQ) Stock Price Up 13% – Here’s Why

Shares of Roquefort Therapeutics plc (LON:ROQ) rose 13% on Wednesday . The company traded as high as GBX 1.40 and last traded at GBX 1.30. Approximately 1,295,074 shares were traded during trading, an increase of 25% from the average daily volume of 1,034,176 shares. The stock had previously closed at GBX 1.15.

Roquefort Therapeutics Price Performance

The stock has a fifty day simple moving average of GBX 1.44 and a 200-day simple moving average of GBX 1.64. The company has a market capitalization of £1.96 million, a PE ratio of -1.90 and a beta of 0.05. The company has a current ratio of 0.79, a quick ratio of 3.07 and a debt-to-equity ratio of 12.37.

Insiders Place Their Bets

In related news, insider Dr Darrin Disley acquired 5,000,000 shares of Roquefort Therapeutics stock in a transaction dated Friday, November 21st. The stock was acquired at an average price of GBX 170 per share, for a total transaction of £8,500,000. Insiders own 23.53% of the company’s stock.

Roquefort Therapeutics Company Profile

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.